About Us

BioCheck, Inc., located in South San Francisco, California, USA, was founded in April 1997. We design, develop, and manufacture high-quality In vitro diagnostic immunoassay devices for the worldwide biomedical, pharmaceutical, and scientific research markets. Product categories include Tumor Markers, Cardiac Markers, Steroids, TORCH, Infectious Diseases, Thyroids, and Fertility. BioCheck also offers antibody purification and conjugation services.

In August 2021, BioCheck acquired DRG International, with offices in the USA, Germany, Russia, Poland, and Czech Republic. BioCheck is an ISO 13485:2016 certified and U.S. FDA 21 CFR Part 820 compliant company that provides quality products and is committed to best-in-class customer care. Together with the DRG subsidiaries, we have the capacity to quickly provide reliable and sensitive products to our customers and distribute our products across the globe. Our goal is to provide timely information so treatment can be implemented earlier and effectiveness can be analyzed sooner, to better the long-term outcomes and improve lives.